• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".

作者信息

Borodic Gary E, Hinkle David M

出版信息

Ophthalmic Plast Reconstr Surg. 2013 May-Jun;29(3):241. doi: 10.1097/IOP.0b013e31828957c3.

DOI:10.1097/IOP.0b013e31828957c3
PMID:23652295
Abstract
摘要

相似文献

1
Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".回复：关于“CTLA - 4受体抑制导致药物性格雷夫斯病”
Ophthalmic Plast Reconstr Surg. 2013 May-Jun;29(3):241. doi: 10.1097/IOP.0b013e31828957c3.
2
Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".关于：“CTLA-4受体抑制引发的药物性格雷夫斯病”
Ophthalmic Plast Reconstr Surg. 2013 May-Jun;29(3):239-40. doi: 10.1097/IOP.0b013e3182895795.
3
Drug-induced graves disease from CTLA-4 receptor suppression.药物诱导的 CTLA-4 受体抑制相关格雷夫斯病。
Ophthalmic Plast Reconstr Surg. 2011 Jul-Aug;27(4):e87-8. doi: 10.1097/IOP.0b013e3181ef72a1.
4
Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression.伊匹单抗诱导的眼眶炎症，类似格雷夫斯病，随后因细胞毒性T淋巴细胞相关抗原4（CTLA-4）受体抑制而出现全身性甲状腺功能亢进。
Ophthalmic Plast Reconstr Surg. 2014 Jan-Feb;30(1):83. doi: 10.1097/IOP.0000000000000033.
5
A case of drug-induced Graves' Orbitopathy after combination therapy with Tremelimumab and Durvalumab.曲美木单抗与度伐利尤单抗联合治疗后发生药物性格雷夫斯眼眶病1例。
J Endocrinol Invest. 2018 Jul;41(7):877-878. doi: 10.1007/s40618-018-0906-0. Epub 2018 May 26.
6
Anti-CTLA4 antibody-induced lupus nephritis.抗CTLA4抗体诱导的狼疮性肾炎。
N Engl J Med. 2009 Jul 9;361(2):211-2. doi: 10.1056/NEJMc0904283.
7
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.阿仑单抗（Campath-1H）诱导的甲状腺眼病的眼部表现
Ophthalmic Plast Reconstr Surg. 2016 Nov/Dec;32(6):e128-e129. doi: 10.1097/IOP.0000000000000310.
8
Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients.伊朗患者中CTLA-4基因多态性与格雷夫斯病及眼病的关联
Eur J Intern Med. 2009 Jul;20(4):424-8. doi: 10.1016/j.ejim.2008.12.005. Epub 2009 Feb 20.
9
Types of colitis based on histology.基于组织学的结肠炎类型。
Dis Mon. 2011 Sep;57(9):457-89. doi: 10.1016/j.disamonth.2011.05.004.
10
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.抗 CTLA-4 抗体免疫治疗黑色素瘤的最新进展：识别临床和生物学反应模式、免疫相关不良反应及其管理。
Semin Oncol. 2010 Oct;37(5):485-98. doi: 10.1053/j.seminoncol.2010.09.003.

引用本文的文献

1
Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment.接受纳武单抗治疗的甲状腺功能正常患者出现严重炎症性眼病
Eur Thyroid J. 2018 Mar;7(2):84-87. doi: 10.1159/000485742. Epub 2018 Jan 4.
2
Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.转移性黑色素瘤中抗细胞毒性T淋巴细胞相关抗原4抗体治疗的免疫介导不良事件。
Transl Res. 2015 Nov;166(5):412-24. doi: 10.1016/j.trsl.2015.06.005. Epub 2015 Jun 11.
3
Ocular side effects of biological agents in oncology: what should the clinician be aware of?
肿瘤学中生物制剂的眼部副作用：临床医生应注意什么？
Onco Targets Ther. 2013 Dec 24;7:69-77. doi: 10.2147/OTT.S54606.